India’s cheap GLP-1 generics risk nutrition gaps amid supplement quality crisis
India is expected to see a GLP-1 boom as Novo Nordisk’s semaglutide patent has expired in the country this month. GLP-1s like Wegovy and Ozempic have made massive impacts in diabetes and weight loss treatments, especially in the US. The expiring patent marks a major moment for India’s pharma and nutrition sectors, as local drug makers have launched and are planning to bring cheaper alternatives, thereby increasing global access for millions suffering from chronic diseases.This Technical Paper is brought to you by ThreoTech.
Amey Desai, sales and marketing director in nutrition from Seppic, spotlighted the convergence of the beauty, wellness, and health markets, pointing to a shift from superficial anti-aging solutions to more holistic, long-term approaches focused on cellular health and longevity. He highlighted the growing importance of scientific credibility, clinical validation, and multi-ingredient formulas to support healthspan. Moreover, Desai said there is a rise of consumer-friendly formats, including functional foods, beverages, and gummies.
Settings
- Play Interval
- Slide Duration
- Thumbnail Bar Position
Latest headlines

Botanical wellness boosts Mar 2026

Omega-3 supplement market trendsMar 2026
Multimedia
Amey Desai, sales and marketing director in nutrition from Seppic, spotlighted the convergence of the beauty, wellness, and health markets, pointing to a shift from superficial anti-aging solutions to more holistic, long-term approaches focused on cellular health and longevity. He highlighted...
Upcoming webinars

Where Structure Drives Beauty: From Scalp Health to Skin Radiance
Monteloeder

Innovating Skin Supplements: New Folate Evidence for Beauty from Within
Gnosis by Lesaffre

Megatrends Shaping Tomorrow’s Food
Kerry Health and Nutrition Institute





























